Truist Securities Lowers Humana's Price Target to $260, Maintains Hold Rating

Truist Securities has lowered Humana's (HUM) price target to $260 from $280, but maintained its "Hold" rating. The average analyst price target is $292.78, with a high estimate of $402.23 and a low estimate of $224.00, implying a 30.45% upside from the current price. The estimated GF Value in one year is $629.61, suggesting a 180.52% upside.

Truist Securities has revised its price target for Humana (HUM) to $260, down from the previous $280. Despite this adjustment, the firm has maintained its "Hold" rating on the stock. This move reflects a cautious stance on Humana's future performance within the healthcare sector.

The average analyst price target for Humana currently stands at $292.78, with a high estimate of $402.23 and a low estimate of $224.00. This implies a potential upside of 30.45% from the current price of $224.44. Additionally, the estimated GF Value for Humana in one year is $629.61, suggesting an upside of 180.52% from the current price.

The consensus recommendation from 27 brokerage firms is a "Hold" rating, with an average brokerage recommendation of 2.6. This rating scale ranges from 1 to 5, where 1 signifies a Strong Buy and 5 denotes a Sell.

Truist Securities' latest update underscores a cautious approach to Humana's stock, as analysts continue to monitor the company's performance in the healthcare sector. Investors should closely watch for any further developments and consider the potential implications of these price target revisions.

References:
[1] https://www.marketbeat.com/instant-alerts/truist-financial-has-lowered-expectations-for-humana-nysehum-stock-price-2025-07-16/
[2] https://www.gurufocus.com/news/2981690/humana-hum-truist-securities-lowers-price-target-but-maintains-hold-rating-hum-stock-news